Why Some Pharmacy Liens Face More Challenges Than Others

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | January 24, 2026 | 9 min read

Defense attorneys and adjusters have learned to identify documentation patterns that are easy to challenge — and those that are not. Understanding what drives lien challenges helps PI attorneys choose the right pharmacy partner and manage cases proactively.

Why Some Pharmacy Liens Face More Challenges Than Others

Not all pharmacy lien challenges are created equal. Some challenges succeed — the lien is reduced significantly, or a disputed medication is removed — because the documentation genuinely did not support the claim. Others are reflexive tactics that fall apart when the documentation is sound.

The difference is almost always documentation quality. Experienced defense attorneys and adjusters have worked enough pharmacy lien cases to distinguish between liens backed by clinical analysis and those backed by raw dispensing records. They know which to challenge hard and which to negotiate reasonably.

[!KEY] Experienced adjusters can identify template clinical narratives within the first paragraph — a generic pharmacy narrative that says nothing specific about this patient's injury carries no evidentiary weight and invites aggressive challenge.

This article identifies the documentation patterns that consistently invite scrutiny — and describes what defensible documentation looks like in contrast.

Pattern 1: Template Narratives With No Patient-Specific Analysis

The most common documentation weakness is the generic clinical narrative: language that explains, in general terms, why medications of a certain type might be appropriate for accident injuries — but says nothing specific about this patient's injury, this physician's diagnoses, or why this medication was clinically indicated for this case.

A defense attorney who has seen a hundred of these can identify the template within the first paragraph. Obtaining examples from other cases — which is discoverable — confirms that the "clinical assessment" is boilerplate. At that point, the narrative carries no evidentiary weight. It is marketing language, not a pharmacist's professional opinion.

Defensible documentation names the specific diagnoses documented by the treating physicians (by ICD code or clinical description), explains how each medication addresses those specific conditions, and reflects the clinical judgment of a pharmacist who actually reviewed this case. The language is necessarily different from case to case because the cases are different.

Pattern 2: No Pharmacist Credential Behind the Documentation

Some pharmacy lien operations are structured as dispensing services with documentation generated by staff rather than reviewed by a licensed pharmacist. The records may include clinical-sounding language, but there is no pharmacist who reviewed the case and who can be called to defend the assessment.

When defense counsel challenges a medication on medical necessity grounds, the question they are ultimately asking is: who is the clinical expert who says this medication was appropriate? If the answer is "our documentation team" rather than "Dr. Smith, PharmD, who reviewed the chart and signed the MERIT," the challenge has no professional counterweight.

A lien that comes with documentation signed by a licensed pharmacist who reviewed the patient's injury profile, the treating physician's notes, and the prescribed medication can be defended by that pharmacist if the case goes to trial or arbitration. That professional credential changes the negotiation dynamic.

Pattern 3: Medication Profiles That Look Identical Regardless of the Injury

Defense attorneys and adjusters see large numbers of lien cases from the same providers. Over time they notice patterns: every patient from a given provider appears to be on Qulipta, or every patient is on the same set of six medications regardless of whether the injury was a soft tissue strain or a herniated disc with radiculopathy.

When medication profiles look uniform across a provider's caseload, it signals that medication selection is not being driven by the clinical picture. It suggests a formula — likely designed around maximum lien value — rather than individual clinical assessment. This is exactly the over-treatment argument adjusters make most aggressively.

Defensible documentation reflects individualized clinical reasoning. A patient with documented radiculopathy and neuropathic pain has a different medication profile from a patient with soft tissue injuries and sleep disruption. The clinical logic for each medication is visible in the documentation.

Pattern 4: Prescriptions Not Connected to the Accident Diagnoses

[!KEY] Every prescription in a pharmacy lien should be traceable to a specific accident-related ICD code in the treating physician's record — documentation that makes this connection explicit for each medication closes the most common defense opening before the demand letter is even sent.

Standard dispensing records show what was dispensed and when. They do not establish why — specifically, they do not connect each prescription to the accident-related diagnoses documented by the treating physicians.

This gap creates an opening for the defense's favorite argument: the medications were prescribed for pre-existing conditions and are not accident-related. Without documentation explicitly establishing the connection between the accident diagnoses and the prescribed medications, the challenge is difficult to rebut.

Defensible documentation identifies the treating physician's documented diagnoses, cross-references the prescription dates with the accident timeline, and explains the causal relationship for each medication. This is the work of clinical analysis, not record retrieval.

Pattern 5: Documentation That Reads as Advocacy

There is a quality that experienced readers of clinical documentation recognize immediately: the difference between a document written to accurately describe the clinical situation and a document written to advocate for the maximum possible claim.

Advocacy documentation tends to:

• Use superlative language about injury severity without clinical basis
• Omit clinical concerns or counterarguments
• Frame every medication as absolutely essential with no gradations
• Be internally consistent in a way that actual clinical documentation rarely is — because clinical situations are complicated and nuanced

This quality of advocacy is detectable, and it is counterproductive. When documentation reads as advocacy, it invites scrutiny precisely because it appears calibrated. A skilled cross-examiner will look for what was left out, what was overstated, and where the documentation diverges from the actual clinical record.

Neutral clinical documentation that accurately represents what a pharmacist found — including limitations, uncertainties, and the distinction between clearly indicated medications and those that were reasonable but not essential — is harder to attack because it was not designed to be perfect. It was designed to be accurate.

Pattern 6: Specialty Medications Without Documented Clinical Rationale

High-cost specialty medications — CGRP agents for migraine, atypical antipsychotics prescribed for PTSD, orexin antagonists for sleep — require clinical justification that is specific to the drug class, not just to the condition.

If a patient is prescribed Aimovig for post-traumatic migraine, the documentation should explain why the patient was placed on a CGRP monoclonal antibody — typically that first-line preventives were inadequate or contraindicated, that the patient's migraine burden was sufficient to warrant prevention, and that the prescribing physician made a deliberate clinical choice to use a CGRP-pathway agent.

Generic language that says "this patient has migraines and Aimovig treats migraines" does not justify the specialty medication. It invites the argument that topiramate or amitriptyline would have been equally appropriate at a fraction of the cost.

Documentation that explains the drug class choice, the clinical reasoning behind the specific agent selected, and the context in which the treating physician determined it was appropriate is documentation that the defense has to work to rebut.

[!TIP] When evaluating a pharmacy lien partner, ask whether their clinical narratives are signed by a named licensed pharmacist who reviewed this case — if the answer is no, the documentation will not hold up to a challenge asking "who is the clinical expert who says this medication was appropriate?"

The Documentation Standard That Prevents All of These

[!KEY] Neutral clinical documentation that acknowledges the distinction between clearly indicated medications and those that were reasonable but not essential is harder to attack than advocacy documentation — because an honest assessment has nothing for cross-examination to find.

The pattern across all six failure modes is the same: documentation that cannot answer "why this, for this patient, for this injury."

Documentation that can answer that question — specifically, with reference to this patient's clinical record — is documentation that gives defense counsel nothing to work with that the documentation does not already address.

This standard requires:

• Pharmacist review of every case, not just dispensing
• Patient-specific clinical narrative that identifies the accident diagnoses and connects each medication to them
• Drug-class justification for specialty medications
• Neutral presentation of the clinical findings rather than advocacy for the maximum claim
• Pharmacist credential behind the documentation — a professional who can be called to testify and who stands behind the assessment

These are the documentation standards that allow pharmacy liens to survive scrutiny. They are achievable. They require clinical infrastructure. And they are the standard by which any pharmacy lien provider should be evaluated before recommending one to a client.

Contact LienScripts to discuss how our clinical documentation standards are built into every case.

Related Resources

• How to Evaluate a Pharmacy Lien Provider Before Recommending One
• Top Adjuster Attacks on Pharmacy Liens — And How to Rebut Them
• What Is a MERIT Report?
• Pharmacy Audit: What to Expect When Liens Are Reviewed